Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adc Therapeutics Sa (NY: ADCT ) 3.070 +0.250 (+8.87%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Adc Therapeutics Sa < Previous 1 2 3 4 Next > ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update August 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan August 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 July 30, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan July 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes June 27, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan June 03, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 15, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference May 09, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma May 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan May 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 May 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma April 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 April 03, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Makes Grants to New Employees Under Inducement Plan April 01, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates March 13, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit March 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 March 06, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference February 27, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards January 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Provides Business Updates January 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) December 12, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards November 07, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates November 07, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the Jefferies London Healthcare Conference November 06, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting November 02, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023 October 24, 2023 From ADC Therapeutics SA Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.